OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

NCT00064428 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

12092

Enrollment

INDUSTRY

Sponsor class

Conditions

Thromboembolism

Interventions

DRUG: fondaparinux - UFH not indicated
OTHER: Control - UFH not indicated
DRUG: Fondaparinux - UFH indicated
DRUG: Control - UFH

Sponsor

GlaxoSmithKline

Collaborators

[object Object]